Literature DB >> 25270945

Momentum builds around new antibiotic business models.

Asher Mullard.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 25270945     DOI： 10.1038/nrd4455

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  1 in total

1.  Approval and withdrawal of new antibiotics and other antiinfectives in the U.S., 1980-2009.

Authors:  Kevin Outterson; John H Powers; Enrique Seoane-Vazquez; Rosa Rodriguez-Monguio; Aaron S Kesselheim
Journal:  J Law Med Ethics       Date:  2013       Impact factor: 1.718
  1 in total
  4 in total

1.  2014 FDA drug approvals.

Authors:  Asher Mullard
Journal:  Nat Rev Drug Discov       Date:  2015-02       Impact factor: 84.694

2.  Peripheral modifications of [Ψ[CH2NH]Tpg4]vancomycin with added synergistic mechanisms of action provide durable and potent antibiotics.

Authors:  Akinori Okano; Nicholas A Isley; Dale L Boger
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-30       Impact factor: 11.205

3.  Introduction: DRIVE-AB's definitions and indicators to monitor responsible antibiotic use.

Authors:  S Harbarth; J Hackett
Journal:  J Antimicrob Chemother       Date:  2018-06-01       Impact factor: 5.790

4.  Heterologous Catalysis of the Final Steps of Tetracycline Biosynthesis by Saccharomyces cerevisiae.

Authors:  Ehud Herbst; Arden Lee; Yi Tang; Scott A Snyder; Virginia W Cornish
Journal:  ACS Chem Biol       Date:  2021-07-16       Impact factor: 5.100
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.